Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NervGen Pharma (NGEN) has closed a non-brokered private placement  for aggregate gross proceeds of $2,321,075
  • The company issued 892,721 units at a price of $2.60 per unit
  • Proceeds will be used for the continued development of their lead drug candidate, NVG-291, and general corporate purposes
  • NervGen is restoring life’s potential by creating innovative treatments for nervous system injury
  • NervGen Pharma Corp. (NGEN) is up 6.77 per cent on the day, trading at 2.84 per share at 12 pm EST

NervGen Pharma (NGEN) has closed a non-brokered private placement for aggregate gross proceeds of $2,321,075.

The company issued 892,721units at a price of $2.60 per unit.

“We appreciate the support of our shareholders, many of whom were unable to fully participate in our recent financing,” said Bill Radvak, NervGen’s Executive Chairman.

“These funds will support our ongoing development programs and importantly, the increased legal, insurance and other costs associated with a potential up-listing to a senior US exchange in the near future.”

Each unit issued consisted of one common share and one-half of one common share purchase warrant. Each warrant is exercisable into one common share at a price of $3.20 per share until November 29, 2023.

All of the securities issued are subject to a four month and one day hold period.

Proceeds will be used for the continued development of their lead drug candidate, NVG-291, and general corporate purposes.

NervGen Pharma paid certain finders a cash fee totaling $20,430.

NervGen is restoring life’s potential by creating innovative treatments for nervous system injury due to trauma or disease of the nervous system. 

NervGen Pharma Corp. (NGEN) is up 6.77 per cent on the day, trading at 2.84 per share at 12 pm EST.

More From The Market Herald
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK MHRA.

" Telo Genomics (TSXV:TELO) advances lead product and Implements automation to workflow

Telo Genomics (TELO) has announced a study for its lead product for smoldering multiple myeloma (SMM) patients and completed research and development projects.

" Cardiol Therapeutics (TSX:CRDL) appoints leaders in cardiovascular medicine to scientific advisory board

Cardiol Therapeutics (CRDL) has appointed Dr. Paul M. Ridker, Dr. Bruce McManus, and Dr. Joseph A. Hill to its scientific advisory board.